ArticleActa oncologica (Stockholm, Sweden)2025
The association between lymph node status and the tumor size in breast cancer - results from the Danish Breast Cancer Group (DBCG).
Article in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sentinel Lymph Node Biopsy for Prophylactic Mastectomy: Necessary Precaution or Unnecessary Procedure?Annals of surgical oncology · 2026Article
- A multimodal ultrasound-based model combining tumor radiomics and axillary lymph node morphologic classification for predicting axillary nodal burden in breast cancer.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThe association between the tumor size and the risk of lymph node metastasis (LNM) is well known. The purpose of this study is to describe a new model for predicting the occurrence of LNM at an earlier time for breast cancer patients where at a given time this association is known. Patient/material and methods: The subjects studied were 59,400 breast cancer patients treated in the period 1995-2012 and registered in the Danish Breast Cancer Group (DBCG) database. Data included age, year of treatment, menopausal status, tumor size, lymph node status, localization, focality, histological type, grade, estrogen receptor (ER), HER2 status, lympho-vascular invasion (LVI), and type of surgery. Univariate and multivariate analyses were made.
results46% of patients presented with LNM. The occurrence increased with increasing tumor size. HER2 positive tumors had more LNM 56.9% versus 44.7% (p < 0.001) (odds ratio [OR] 1.17 [95% confidence interval, CI 1.09-1.26]) and mostly pronounced in relation to ER negative tumors (p < 0.001). ER negative/HER2 negative tumors had lower risk of LNM (OR 0.57 [95% CI 0.52-0.63]). Central tumors and tumors in the lower lateral quadrant were more often node positive. LVI showed increased odds for LNM (OR 5.16 [95% CI 4.84-5.52]).
interpretationIncreasing tumor size is the only time-dependent risk of LNM. HER2 positive tumors had an increased risk of LNM, and ER negative/HER2 negative tumors had a decreased risk of LNM. LVI was associated with substantial increased risk of LNM. The knowledge of breast cancer patient and tumor characteristics at a given time may predict stage of cancer at an earlier time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.